NO20050294L - Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser - Google Patents

Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser

Info

Publication number
NO20050294L
NO20050294L NO20050294A NO20050294A NO20050294L NO 20050294 L NO20050294 L NO 20050294L NO 20050294 A NO20050294 A NO 20050294A NO 20050294 A NO20050294 A NO 20050294A NO 20050294 L NO20050294 L NO 20050294L
Authority
NO
Norway
Prior art keywords
obesity
diabetes
treatment
type
cns disorders
Prior art date
Application number
NO20050294A
Other languages
English (en)
Norwegian (no)
Inventor
Gary Johansson
Annika Jenmalm-Jensen
Katarina Beierlein
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/xx
Priority claimed from SE0202181A external-priority patent/SE0202181D0/xx
Priority claimed from SE0202908A external-priority patent/SE0202908D0/xx
Priority claimed from SE0300357A external-priority patent/SE0300357D0/xx
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20050294L publication Critical patent/NO20050294L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20050294A 2002-06-20 2005-01-19 Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser NO20050294L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (sv) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (sv) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (sv) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (sv) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
NO20050294L true NO20050294L (no) 2005-02-04

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050294A NO20050294L (no) 2002-06-20 2005-01-19 Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser

Country Status (13)

Country Link
EP (1) EP1513828A1 (de)
CN (1) CN1662521A (de)
AU (1) AU2003243091A1 (de)
BR (1) BR0311952A (de)
CA (1) CA2486989A1 (de)
EA (2) EA008835B1 (de)
IL (1) IL165051A0 (de)
MX (1) MXPA04012914A (de)
NO (1) NO20050294L (de)
NZ (3) NZ552283A (de)
RS (1) RS111204A (de)
SG (1) SG156524A1 (de)
WO (1) WO2004000828A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
BRPI0417833A (pt) * 2003-12-19 2007-04-17 Biovitrum Ab novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
JP4926943B2 (ja) * 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (es) * 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
US7582767B2 (en) * 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
BRPI0618206A2 (pt) 2005-11-03 2011-08-23 Hoffmann La Roche arilsulfonil cromanos como inibidores de 5-ht6, bem como composição farmacêutica, uso e processo para produção dos mesmos
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
CA2654822A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
BRPI0713502A2 (pt) 2006-06-20 2012-03-13 F. Hoffmann-La Roche Ag derivados de tetralina de arilsulfonamidil e empregos destes
CN101472884A (zh) 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其用途
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2508177A1 (de) 2007-12-12 2012-10-10 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2012154194A1 (en) * 2011-05-09 2012-11-15 Forma Tm, Llc Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
ATE201403T1 (de) * 1993-03-16 2001-06-15 Pfizer Naphtalinderivate
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2001085722A1 (en) * 2000-05-05 2001-11-15 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
JP2004503553A (ja) * 2000-06-14 2004-02-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ６，５−縮合二環式複素環
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
WO2002092585A1 (en) * 2001-05-11 2002-11-21 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
EP1401813B1 (de) * 2001-06-07 2007-02-07 F. Hoffman-la Roche AG Neue indolderivate mit affinität zum 5-ht6-rezeptor
IL158590A0 (en) * 2001-06-11 2004-05-12 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Also Published As

Publication number Publication date
EA011581B1 (ru) 2009-04-28
SG156524A1 (en) 2009-11-26
IL165051A0 (en) 2005-12-18
AU2003243091A1 (en) 2004-01-06
EA200600975A1 (ru) 2006-10-27
WO2004000828A1 (en) 2003-12-31
EA200500054A1 (ru) 2005-06-30
RS111204A (sr) 2006-12-15
EP1513828A1 (de) 2005-03-16
BR0311952A (pt) 2005-04-19
MXPA04012914A (es) 2005-03-31
NZ552283A (en) 2008-07-31
CA2486989A1 (en) 2003-12-31
EA008835B1 (ru) 2007-08-31
NZ552282A (en) 2008-07-31
CN1662521A (zh) 2005-08-31
NZ536600A (en) 2007-08-31

Similar Documents

Publication Publication Date Title
NO20050294L (no) Nye forbindelser nyttige i behandlingen av fedme, type II diabetes og CNS forstyrrelser
SE0403006D0 (sv) New compounds
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
YU98003A (sh) Supstituisana sulfonamidna jedinjenja, postupak za njihovu upotrebu kao leka za tretiranje poremećaja cns, gojaznosti i dijabetesa tipa ii
NO20050828L (no) lndol-3-svovelderivater
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20082496L (no) Pyrazinderivater
NO972091L (no) Bestemte substituerte benzylaminderivater; en ny klasse nouropeptid-yl-spesifikke ligander
CA2443724A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
NO20076515L (no) Hydantoinforbindelser
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20053792L (no) Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander
NO20071222L (no) Benzamidforbindelser.
NO20032841L (no) Heterocykloindol- eller azaindol-forbindelser som 5- hydroksytryptamin-6-ligander
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
NO20080354L (no) Benzofuranylderivater som 5-HT6-reseptorinhibitorer
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
SE0303480D0 (sv) Benzofuranes
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application